Adicet Bio (ACET) Expected to Announce Earnings on Wednesday

Adicet Bio (NASDAQ:ACET) will likely be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Adicet Bio to post earnings of ($0.26) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02). On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Stock Performance

Adicet Bio stock opened at $0.73 on Tuesday. The stock’s 50 day moving average price is $0.84 and its 200 day moving average price is $0.74. The firm has a market capitalization of $60.77 million, a PE ratio of -0.56 and a beta of 1.61. Adicet Bio has a one year low of $0.45 and a one year high of $1.40.

Institutional Investors Weigh In On Adicet Bio

An institutional investor recently raised its position in Adicet Bio stock. Goldman Sachs Group Inc. boosted its holdings in shares of Adicet Bio, Inc. (NASDAQ:ACET) by 1.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,816,556 shares of the company’s stock after purchasing an additional 63,691 shares during the quarter. Goldman Sachs Group Inc. owned approximately 4.61% of Adicet Bio worth $2,882,000 at the end of the most recent quarter. Institutional investors and hedge funds own 83.89% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ACET. Jefferies Financial Group raised Adicet Bio to a “strong-buy” rating in a research report on Tuesday, October 7th. Guggenheim boosted their price target on Adicet Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. HC Wainwright raised Adicet Bio to a “strong-buy” rating and set a $4.00 price target on the stock in a research report on Wednesday, July 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adicet Bio in a research report on Thursday, October 30th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $5.67.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.